Are YOU a Slow/Non-Responder to GLP-1's?
US$ 27.68
retatrutide microdosing protocol Chart: Week-by-Week Dose and IU Reference Retatrutide dose: the complete guide
Description
Longevity at a premium.
Why Lab Testing Is Key to Safer, Smarter GLP-1 Therapy
Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP receptor agonist undergoing evaluation for MASH after demonstrating significant liver fat reduction in studies.Retatrutide: A "triple agonist" targeting GLP-1, GIP, and glucagon (GCGR) receptors, which has shown "unprecedented" efficacy in weight loss and is being evaluated for metabolic diseases including MASH
95% CI, 0.89 to 1.42)
Certain genetic variants, carried by around 10 percent of the population, could be making type 2 diabetes GLP-1 treatments (such as Ozempic and Wegovy) less effective, according to new research.
